PPARβ/δ Regulates Glucocorticoid- and Sepsis-Induced FOXO1 Activation and Muscle Wasting

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Castillero, Estibaliz ^a   Alamdari, Nima ^a   Aversa, Zaira ^a   Gurav, Aniket ^a   Hasselgren, Per Olof ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; ATROGIN 1; GLUCOCORTICOID; MUSCLE RING FINGER 1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TRANSCRIPTION FACTOR FKHR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; MALE; MUSCLE ATROPHY; MUSCLE MASS; MYOTUBE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RAT; SEPSIS; UPREGULATION;

ANIMALS; CELL NUCLEUS; DEXAMETHASONE; FORKHEAD TRANSCRIPTION FACTORS; GLUCOCORTICOIDS; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLES; MUSCULAR ATROPHY; NERVE TISSUE PROTEINS; PPAR DELTA; PPAR-BETA; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; RNA, SMALL INTERFERING; SEPSIS; SKP CULLIN F-BOX PROTEIN LIGASES; THIAZOLES; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 84875318722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059726     Document Type: Article

References (87)

1. Aversa Z, Alamdari N, Hasselgren PO, (2011) Molecules modulating gene transcription during muscle wasting in cancer, sepsis and other critical illness. Crit Rev Clin Lab Sci 48: 71-86.
2. Hasselgren PO, Alamdari N, Aversa Z, Gonnella P, Smith I, et al. (2010) Corticosteroids and muscle wasting - role of transcription factors, nuclear cofactors, and hyperacetylation. Curr Opin Clin Nutr Metabol Care 13: 423-428.
3. Schakman O, Gilson H, Thissen JP, (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197: 1-10.
4. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL, (2001) Atrogin-1, a muscle specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98: 14440-14445.
5. Bodine SC, Latres E, Baumheuter S, Lai VK, Nunez L, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708.
6. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, et al. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51.
7. Foletta VC, White LJ, Larsen AE, Leger B, Russell AP, (2011) The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. Eur J Physiol 461: 325-335.
8. Furuyama T, Kitayama K, Yamashita H, Mori N, (2003) Fork head transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J 375: 365-371.
9. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, et al. (2004) Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type 1 (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 279: 41114-41123.
10. Nakashima K, Yakabe Y, (2007) AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem 71: 1650-1656.
11. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, at al, (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412.
12. Smith I, Alamdari N, O'Neal P, Gonnella P, Aversa Z, et al. (2010) Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism. Int J Biochem Cell Biol 42: 701-711.
13. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, et al. (2008) The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am. J. Physiol. Endocrinol Metab 295: E785-E797.
14. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. (2004) Stress-dependent regulation of FoxO transcription factors by the Sirt1 deacetylase. Science 303: 2011-2015.
15. Katoh M, (2004) Human Foxo gene family. Int J Oncol 25: 1495-1500.
16. Van der Heide LP, Hoekmann MFM, Smidt MP, (2004) The ins and outs of FoxO shuttling: mechanism of FoxO translocation and transcriptional regulation. Biochem J 380: 297-309.
17. Hasselgren PO, (2007) Ubiquitination, phosphorylation, and acetylation - triple threat in muscle wasting. J Cell Physiol 213: 679-689.
18. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, et al. (2007) Foxo3 controls autophagy in skeletal muscle in vivo. Cell Metab 6: 458-471.
19. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, et al. (2007) FoxO3 coordinately activates protein degradation by the autophagic/lysosomal pathways in atrophying muscle. Cell Metab 6: 472-483.
20. Nahle Z, Hsieh M, Pietka T, Coburn CT, Grimaldi PA, et al. (2008) CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPARβ/δ-mediated adaptation to metabolic stress. J Biol Chem 283: 14317-14326.
21. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, et al. (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142: 4195-4202.
22. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, et al. (2008) Quantitative expression patterns of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) protein in mice. Biochem Biophys Res Commun 371: 456-461.
23. Peters JM, Hollingshead HE, Gonzalez FJ, (2008) Role of peroxisome-proliferator-activated receptor beta/delta (PPAR beta/delta) in gastrointestinal tract function and disease. Clin Sci 115: 107-127.
24. Peters JM, Gonzalez FJ, (2009) Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPAR beta/delta) in cell proliferation and cancer. Biochim Biophys Acta 1796: 230-241.
25. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, et al. (2006) PPAR delta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103: 3444-3449.
26. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, et al. (2002) Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knockout mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 277: 26089-26097.
27. Constantin D, Constantin-Teodosiu D, Layfield R, Tsintzas K, Bennett AJ, et al. (2007) PPARδ agonism induces a change in fuel metabolism and activation of an atrophy programme, but does not impair mitochondrial function in rat skeletal muscle. J Physiol 583 (1) (): 381-390.
28. Tiao G, Lieberman MA, Fischer JE, Hasselgren PO, (1997) Intracellular regulation of protein degradation during sepsis is different in fast- and slow-twitch muscle. Am J Physiol Regul Integr Comp Physiol 272: R849-R856.
29. Fuster G, Busquets S, Ametller E, Olivan M, Almendro V, et al. (2007) Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of β2-adrenergic agonists. Cancer Res 67: 6512-6579.
30. Gonnella P, Alamdari N, Tizio S, Aversa Z, Petkova V, et al. (2011) C/EBPβ regulates dexamethasone-induced muscle cell atrophy and expression of atrogin-1 and MuRF1. J Cell Biochem 112: 1737-1748.
31. Menconi M, Gonnella P, Petkova V, Lecker S, Hasselgren PO, (2008) Dexamethasone and corticosterone induce similar, but not identical muscle wasting responses in cultured L6 and C2C12 myotubes. J Cell Biochem 105: 353-364.
32. Rihai Y, Sin-Malia Y, Cohen G, Alpert E, Gruzman A, et al. (2010) The natural protective mechanism against hyperglycemia in vascular endothelial cells. Roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor δ. Diabetes 59: 808-818.
33. Naruhn S, Toth PM, Adhikary T, Kaddatz K, Pape V, et al. (2011) High-affinity peroxisome proliferator-activated receptor β/δ-specific ligands with pure antagonistic or inverse agonistic properties. Mol Pharmacol 80: 828-838.
34. Wang L, Luo GJ, Wang JJ, Hasselgren PO, (1998) Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured L6 myotubes. Shock 10: 298-306.
35. Tiao G, Fagan J, Roegner V, Lieberman M, Wang JJ, et al. (1996) Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J Clin Invest 97: 339-348.
36. Alamdari N, Smith IJ, Aversa Z, Hasselgren PO, (2010) Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 299: R509-R520.
37. Menconi MJ, Arany ZP, Alamdari N, Aversa Z, Gonnella P, et al. (2010) Sepsis and glucocorticoids downregulate the expression of the nuclear cofactor PGC-1β in skeletal muscle. Am J Physiol Endocrinol Metab 299: E533-E543.
38. Hall-Angerås M, Angerås U, Zamir O, Hasselgren PO, Fischer JE, (1991) Effect of the glucocorticoid receptor antagonist RU 38486 on muscle protein breakdown in sepsis. Surgery 109: 468-473.
39. Wray CJ, Mammen JMV, Hershko D, Hasselgren PO, (2003) Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 35: 698-705.
40. Zamir O, Hasselgren PO, Frederick JA, Fischer JE, (1992) Is the metabolic response to sepsis in skeletal muscle different in infants and adults? An experimental study in rats. J Pediatr Surg 27: 1399-1403.
41. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, et al. (1997) Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 99: 163-168.
42. Sanchez-Siles AA, Ishimura N, Rumi MA, Tamagawa Y, Ito S, et al. (2011) Administration of PPARβ/δ agonist reduces copper-induced liver damage in mice: possible implications in clinical practice. J Clin Biochem Nutr 49: 42-49.
43. Williams AB, DeCourten-Meyers GM, Fischer JE, Luo G, Sun X, et al. (1999) Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J 13: 1435-1443.
44. Chamberlain W, Gonnella P, Alamdari N, Aversa Z, Hasselgren PO, (2012) Multiple muscle wasting-related transcription factors are acetylated in dexamethasone-treated muscle cells. Biochem Cell Biol 90: 200-208.
45. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) - synthesis and biological activity. Bioorg Med Chem Lett 13: 1517-1521.
46. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, et al. (2008) Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (nrlc2) antagonist. Mol Endocrinol 22: 523-529.
47. Van der Heide LP, Hoekman MFM, Smidt MP, (2004) The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 380: 297-309.
48. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, et al. (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563.
49. Perrot V, Rechter MM, (2005) The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Mol Endocrinol 19: 2283-2298.
50. Alamdari N, Aversa Z, Castillero E, Gurav A, et al. (2012) Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. Biochem Biophys Res Commun 417: 528-533.
51. Johnson TE, Vogel R, Rutledge SJ, Rodan G, Schmidt A, (1999) Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 140: 3245-3254.
52. Lemberger T, Staels B, Saladin R, Desvergne B, Auwerx J, et al. (1994) Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids. J Biol Chem 269: 24527-24530.
53. Lemberger T, Saladin R, Vázquez M, Assimacopoulos F, Staels B, et al. (1996) Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem 271: 1764-1769.
54. Nie M, Corbett L, Knox AJ, Pang L, (2005) Differential regulation of chemokine expression by peroxisome proliferator-activated receptor γ agonists. Interactions with glucocorticoids and β2-agonists. J Biol Chem 280: 2550-2561.
55. Philibert D (1984) RU38486: an original multifaceted antihormone in vivo. Adrenal Steroid Antagonism. Hawthorne, New York: Walter de Gruyter and Co.
56. Smith IJ, Aversa Z, Alamdari N, Petkova V, Hasselgren PO, (2010) Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle. J Cell Biochem 111: 1059-1073.
57. Sun X, Fischer DR, Pritts TA, Wray CJ, Hasselgren PO, (2002) Expression and binding activity of the glucocorticoid receptor are upregulated in septic muscle. Am J Physiol Regul Integr Comp Physiol 282: R509-R518.
58. Chambers MA, Moylan JS, Reid MB, (2009) Physical inactivity and muscle weakness in the critically ill. Crit Care Med 37: S337-S346.
59. De Jonghe B, Bastuji-Garin S, Sharshar T, Autin H, Brochard L, (2004) Does ICU-acquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med 30: 1117-1121.
60. Herridge MS, (2009) Legacy of intensive care unit-acquired weakness. Crit Care Med 37: S457-S46.1.
61. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, et al. (2008) Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 358: 1327-1335.
62. Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, et al. (2004) Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 18: 1144-1146.
63. Holloway GP, Benton CR, Mullen KL, Yoshida Y, Snook LA, et al. (2009) In obese rat muscle transport of palmitate is increased and is channeled to triacylglycerol storage despite an increase in mitochondrial palmitate oxidation. Am J Physiol Endocrinol Metab 296: E738-E747.
64. Schwenk RW, Holloway GP, Luiken JJFP, Bonen A, Glatz JFC, (2010) Fatty acid transport across the cell membrane: Regulation by fatty acid transporters. Prostagl Leukotr Ess Fatty Acids 82: 149-154.
65. Wang XJ, Song ZG, Jiao HC, Lin H, (2011) Dexamethasone facilitates lipid accumulation in chicken skeletal muscle. Stress 2012 15(4): 443-56.
66. Barnes PJ, Adcock IM, (2003) How do corticosteroids work in asthma? Ann Intern Med 139: 359-370.
67. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, et al. (2000) Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. J Biol Chem 275: 33201-33204.
68. Needham M, Raines S, McPheat J, Stacey C, et al. (2000) Differential interaction of steroid hormone receptors with LXXLL motifs in SRC-1a depends on residues flanking the motif. J Steroid Biochem Mol Biol 72: 35-46.
69. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, et al. (2004) Iκκβ/NF-κB activation causes severe muscle wasting in mice. Cell 119: 285-298.
70. Penner CG, Gang G, Wray C, Fischer JE, Hasselgren PO, (2001) The transcription factors NF-kB and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun 281: 1331-1336.
71. Van Gammeren D, Damrauer JS, Jackman RW, Kandarian S, (2009) The IkB kinases IKKα and IKKβ are necessary and sufficient for skeletal muscle atrophy. FASEB J 23: 362-370.
72. Zhang G, Jin B, Li YP, (2011) C/EBPβ mediates tumor-induced ubiquitin ligase atrogin-1/MAFbx upregulation and muscle wasting. EMBO J 30: 4323-4335.
73. Coll T, Alvarez-Guardia D, Barroso E, Gómez-Foix AM, Palomer X, et al. (2010) Activation of peroxisome proliferator-activated receptor-δ by GW 501516 prevents fatty acid-induced nuclear factor-kB activation and insulin resistance in skeletal muscle cells. Endocrinology 151: 1560-1569.
74. Krämer DK, Al-Khalili L, Perrini S, Skogsberg J, Wretenberg P, et al. (2005) Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ. Diabetes 54: 1157-1163.
75. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, et al. (2003) Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J 17: 2299-2301.
76. Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, et al. (2006) PGC-1α expression is controlled in skeletal muscle by PPARβ, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab 4: 407-414.
77. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, et al. (2004) Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biology 2: e294.
78. Dhar A, Castillo L, (2011) Insulin resistance in critical illness. Curr Opin Pediatr 23: 269-274.
79. Wang X, Hu Z, Hu J, Du J, Mitch WE, (2006) Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147: 4160-4168.
80. Vanasco V, Cimolai MC, Evelson P, Alvarez S, (2008) The oxidative stress and the mitochondrial dysfunction caused by endotoxemia are prevented by alpha-lipoic acid. Free Radic Res 42: 815-823.
81. Fredriksson K, Rooyackers O, (2007) Mitochondrial function in sepsis: respiratory versus leg muscle. Crit Care Med 35: S449-S453.
82. Debard C, Cozzone D, Ricard N, Vouillarmet J, Disse E, et al. (2006) Short-term activation of peroxisome proliferator-activated receptor β/δ increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients. J Mol Med 84: 747-752.
83. Terada S, Wicke S, Holloszy JO, Han DH, (2006) PPARδ activator GW-501516 has no acute effect on glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab 290: E607-E611.
84. Dimopoulos N, Watson M, Green C, Hundal HS, (2007) The PPARδ agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilization or insulin sensitivity in rat L6 skeletal muscle cells. FEBS Lett 581: 4743-4748.
85. Cresser J, Bonen A, Chabowski A, Stefanyk LE, Gulli R, et al. (2010) Oral administration of a PPAR-δ agonist worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers. Am J Physiol Regul Integr Comp Physiol 299: R470-R479.
86. Brunnmair B, Staniek K, Dörig J, Szöcs Z, Stadlbauer K, et al. (2006) Activation of PPAR-δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia 49: 2713-2722.
87. Fosslien E, (2001) Mitochondrial medicine - molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 31: 25-67.